About jaguar health inc - JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
JAGX At a Glance
Jaguar Health, Inc.
200 Pine Street
San Francisco, California 94104
| Phone | 1-415-371-8300 | Revenue | 11.51M | |
| Industry | Pharmaceuticals: Major | Net Income | -53,434,000.00 | |
| Sector | Health Technology | Employees | 47 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
JAGX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.189 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.91 |
| Enterprise Value to Sales | 3.391 |
| Total Debt to Enterprise Value | 1.117 |
JAGX Efficiency
| Revenue/Employee | 244,914.894 |
| Income Per Employee | -1,136,893.617 |
| Receivables Turnover | 6.779 |
| Total Asset Turnover | 0.251 |
JAGX Liquidity
| Current Ratio | 0.50 |
| Quick Ratio | 0.289 |
| Cash Ratio | 0.193 |
JAGX Profitability
| Gross Margin | 48.084 |
| Operating Margin | -391.869 |
| Pretax Margin | -469.09 |
| Net Margin | -464.199 |
| Return on Assets | -116.48 |
| Return on Equity | N/A |
| Return on Total Capital | -203.032 |
| Return on Invested Capital | -327.364 |
JAGX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 165.693 |
| Total Debt to Total Assets | 113.788 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 60.70 |